A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
Relapsed/Refractory Diffuse Large B-Cell Lymphoma
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 240 (planned)
- Started
- Mar 20, 2026
- Main results expected
- Apr 30, 2028
- Fully finished
- Dec 30, 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-free survival (PFS)
Measured over: Up to approximately two years
End of treatment (EOT)
Measured over: Up to approximately two years
Systemic antitumor therapy
Measured over: Up to approximately two years
Overall survival (OS)
Measured over: Up to approximately two years
systematic anti-tumor therapy
Measured over: Up to approximately two years
Premature withdrawal from study treatment
Measured over: Up to approximately two years
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07409428 · record last updated 2026-07-20 · checked 2026-11-09 15:36 UTC